Volume | 7,460,074 |
|
|||||
News | - | ||||||
Day High | 2.185 | Low High |
|||||
Day Low | 2.06 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.07 | 2.06 | 2.185 | 2.09 | 2.04 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,260 | 7,460,074 | $ 2.13 | $ 15,893,906 | - | 0.70 - 3.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:34:22 | formt | 218 | $ 2.10 | USD |
Esperion Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
388.61M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Esperion Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.12 | 2.5254 | 2.01 | 2.25 | 14,983,672 | -0.02 | -0.94% |
1 Month | 2.47 | 2.54 | 1.71 | 2.13 | 7,753,908 | -0.37 | -14.98% |
3 Months | 2.68 | 3.40 | 1.71 | 2.45 | 7,194,982 | -0.58 | -21.64% |
6 Months | 1.00 | 3.40 | 0.865 | 2.30 | 6,535,184 | 1.10 | 110.00% |
1 Year | 1.40 | 3.40 | 0.70 | 1.96 | 4,875,704 | 0.70 | 50.00% |
3 Years | 22.78 | 26.77 | 0.70 | 3.64 | 2,748,554 | -20.68 | -90.78% |
5 Years | 49.85 | 79.989 | 0.70 | 8.39 | 1,894,194 | -47.75 | -95.79% |
Esperion Therapeutics Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |